Stock Watch: Investor Reactions Diverge As J&J And Novartis Report Q2 Results
A Good Start To Earnings Season Quickly Reverses
Both of the first two companies to report second-quarter financials maintained full-year sales guidance. But while Johnson & Johnson’s investors seemed cheered, Novartis’s may have been concerned about familiar issues.
